186 related articles for article (PubMed ID: 23921604)
1. Reintroduction of imatinib in GIST.
Reid T
J Gastrointest Cancer; 2013 Dec; 44(4):385-92. PubMed ID: 23921604
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
Wang D; Zhang Q; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M; Eisenberg BL
Ann Surg Oncol; 2012 Apr; 19(4):1074-80. PubMed ID: 22203182
[TBL] [Abstract][Full Text] [Related]
4. Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
Gasparotto D; Miolo G; Torrisi E; Canzonieri V; Bertola G; Libra M; Marzotto A; Maestro R; Buonadonna A
Int J Colorectal Dis; 2014 May; 29(5):639-40. PubMed ID: 24525699
[No Abstract] [Full Text] [Related]
5. Gastrointestinal stromal tumors: imatinib and beyond.
Schnadig ID; Blanke CD
Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
[TBL] [Abstract][Full Text] [Related]
6. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.
Al-Batran SE; Hartmann JT; Heidel F; Stoehlmacher J; Wardelmann E; Dechow C; Düx M; Izbicki JR; Kraus T; Fischer T; Jäger E
Gastric Cancer; 2007; 10(3):145-52. PubMed ID: 17922091
[TBL] [Abstract][Full Text] [Related]
7. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F
Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587
[TBL] [Abstract][Full Text] [Related]
9. Emergence of secondary resistance to imatinib in recurrent gastric GIST.
Jayanthi NV
J Gastrointest Surg; 2010 Dec; 14(12):2018-9; author reply 2020. PubMed ID: 20714935
[No Abstract] [Full Text] [Related]
10. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
[TBL] [Abstract][Full Text] [Related]
11. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors.
Eisenberg BL; Trent JC
Int J Cancer; 2011 Dec; 129(11):2533-42. PubMed ID: 21671474
[TBL] [Abstract][Full Text] [Related]
13. [Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
Zhang L; Cai M; Deng J; Wang X; Wang B; Liu N; Pan Y; Zhang R; Cui Q; Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):331-4. PubMed ID: 24760639
[TBL] [Abstract][Full Text] [Related]
14. Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors.
Sicklick JK; Lopez NE
J Gastrointest Surg; 2013 Nov; 17(11):1997-2006. PubMed ID: 23775094
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of imatinib for treatment of metastatic GIST.
Patel S
Cancer Chemother Pharmacol; 2013 Aug; 72(2):277-86. PubMed ID: 23503753
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal stromal tumors: current management.
Pisters PW; Patel SR
J Surg Oncol; 2010 Oct; 102(5):530-8. PubMed ID: 20063363
[TBL] [Abstract][Full Text] [Related]
17. Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.
Pandey R; Kochar R
J Gastrointest Cancer; 2012 Dec; 43(4):547-52. PubMed ID: 22847491
[TBL] [Abstract][Full Text] [Related]
18. [Long-Term Survival by Low-Dose Imatinib after Recurrence of GIST].
Mihara Y; Ando T; Hayashi M; Atsuta K; Nakayama T; Isobe K
Gan To Kagaku Ryoho; 2022 Jan; 49(1):63-65. PubMed ID: 35046364
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant imatinib for GIST: the pie is shrinking.
Balachandran VP; DeMatteo RP
Ann Surg Oncol; 2014 Oct; 21(11):3365-6. PubMed ID: 25120253
[No Abstract] [Full Text] [Related]
20. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Blanke CD; Huse DM
J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]